Evaluation of the risk of bleeding in patients using warfarin combined allopurinol with , benzbromarone and celecoxib.
- At: 2012 FIP Congress in Amsterdam (the Netherlands)
- Type: Poster
- By: CHIEN, MingWen (Cheng Hsin General Hospital, Taipei, China Taiwan)
- Co-author(s): Chang, H.C. (Cheng Hsin General Hospital, Taipei, China Taiwan)
Huang, C.M. (Cheng Hsin General Hospital, Taipei, China Taiwan)
Background: Warfrin is an oral anticoagulant by monitoring the INR to know the side effects of therapy and bleeding.It can easily react with other drugs to cause drug interactions. Moderate or minor drug interactions are often overlooked. Therefore, this discussion of clinical use warfarin focuses on two moderate, low interaction drugs which will.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.